Eisai Co., Ltd. ESALY
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 17.64B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- —
- High
- —
- Earnings
- Feb 2, 2023
News
3 months ago defenseworld.net
Eisai (OTCMKTS:ESALY) Stock Crosses Below 50 Day Moving Average – Time to Sell?
Eisai Co., Ltd. (OTCMKTS:ESALY - Get Free Report) shares crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $61.51 and traded as low as…
6 months ago defenseworld.net
Eisai (OTCMKTS:ESALY) Share Price Crosses Below 50 Day Moving Average – Here’s Why
Shares of Eisai Co., Ltd. (OTCMKTS:ESALY - Get Free Report) crossed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $61.51 and traded as…
6 months ago marketwatch.com
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
1 year ago benzinga.com
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.
1 year ago youtube.com
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing…
1 year ago youtube.com
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
2 years ago cnbc.com
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to…
2 years ago reuters.com
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive…
2 years ago seekingalpha.com
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
Eisai Co Ltd (OTCPK:ESALF) Q1 2025 Results Conference Call August 2, 2024 2:00 AM ET Company Participants Mitsuru Shomon - Chief Financial Officer Keisuke Naito - Representative Corporate Officer and…
2 years ago reuters.com
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data…
2 years ago cnbc.com
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data…
2 years ago reuters.com
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
Shares of Japan's Eisai tumbled 11% and were on track for their biggest one-day fall in three years on Monday, after the European Union's regulator rejected the drugmaker's Leqembi treatment for…
2 years ago prnewswire.com
Eisai will seek re-examination of CHMP opinion för lecanemab
STOCKHOLM , July 26, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products…
2 years ago reuters.com
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eisai and Biogen's breakthrough treatment for early Alzheimer's disease, in a blow to the drugmakers as take-up in the U.S. has been slower…
2 years ago globenewswire.com
Dassault Systèmes: Eisai Selects Medidata's Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
Eisai Selects Medidata's Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
2 years ago seekingalpha.com
Eisai: Margin Of Safety From Very Modest Penetration Expectations
Eisai's story revolves around Leqembi and Lenvima, with Leqembi launching in Japan and expected to reach 10% of necessary revenue for fair value by end of year. Leqembi sales projected to hit 50…
2 years ago reuters.com
Japan's Eisai developing dementia drug for US market, Nikkei reports
Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday.
2 years ago reuters.com
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday.
2 years ago prnewswire.com
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
STOCKHOLM , June 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's…
2 years ago globenewswire.com
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,…
2 years ago prnewswire.com
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass. , June 9, 2024 /PRNewswire/ -- Eisai Co., Ltd.
-
4 years ago benzinga.com
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
-
6 years ago benzinga.com
Earnings Scheduled For August 3, 2020
Companies Reporting Before The Bell • Atlantica Sustainable Inc. (NASDAQ:AY) is estimated to report quarterly earnings at $0.15 per share on revenue of $261.76 million.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday